Merck and Moderna said Wednesday that their personalized mRNA cancer vaccine, known as intismeran autogene, succeeded in its first Phase 3 trial — a result Endpoints News framed as the arrival of "the next generation of immunotherapy."
The readout came at an interim data check. According to BioPharma Dive, investigators on the key melanoma trial found that the individualized mRNA treatment kept disease from returning and stopped it from spreading. BioPharma Dive described the outcome as a "landmark" result.
The idea behind the vaccine is personalization: rather than one formulation for everyone, the treatment is built as an individualized mRNA therapy, the same underlying technology Moderna became famous for during the pandemic — now pointed at cancer instead of an infectious disease.
Wall Street reacted immediately. Moderna's shares soared to multiyear highs after the disclosure, Endpoints News reported. BioPharma Dive put the move in dollars: roughly $45 billion in market value added in a single day, lifting the stock to levels it had not seen since 2024.
That surge is as much about credibility as chemistry. Moderna has said for years that it would diversify its portfolio beyond infectious diseases, Endpoints noted, and investors had been waiting for late-stage proof. This is the first time they have gotten it. Endpoints reported the data eased investor skepticism about the company's future.
The enthusiasm carries its own risk. BioPharma Dive cautioned that the one-day rally has saddled Moderna with expectations that may be tough to meet.
It matters because a positive late-stage result for a personalized mRNA cancer vaccine would mark a shift in how cancer is treated — from off-the-shelf drugs toward therapies built for one patient at a time.